Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

Background: Synucleinopathies such as Parkinson ́s disease (PD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated α-synuclein. Small aggregates (oligomers) of α-synuclein have been shown to be the most relevant neurotoxic s...

Full description

Bibliographic Details
Main Authors: Dalley, J.W (Author), Giese, A. (Author), Griesinger, C. (Author), Langer, S. (Author), Leonov, A. (Author), Levin, J. (Author), Mariner, C. (Author), Matthias, T. (Author), Melbourne, S. (Author), Morgan, A. (Author), Prager, K. (Author), Ryazanov, S. (Author), Schmidt, F. (Author), Sing, N. (Author), Spillantini, M.G (Author), Weckbecker, D. (Author), Wegrzynowicz, M. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
Anle138b
Disease modification
Multiple system atrophy
Parkinson disease
Protein aggregation
α-synuclein
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items